Annex A. Science And Technology Objectives (STOs)
Army Science and Technology Master Plan (ASTMP 1997)

III.J.29. Advanced Anticonvulsant. By FY97, demonstrate safety and efficacy sufficient for a Milestone 0 transition of an advanced anticonvulsant adjunct or component for the soldier/buddy-use nerve agent antidote. Advanced anticonvulsant will overcome deficiencies of current anticonvulsant, Convulsant Antidote for Nerve Agent (CANA); i.e., will be more effective in stopping ongoing convulsive seizures, preventing their recurrence, and protecting against nerve-agent-induced, seizure-related brain damage. It will also demonstrate less abuse potential than CANA. Achieve Milestone 1 transition by FY99.

Supports: Development of Food and Drug Administration-licensed anticonvulsant for nerve agent therapy; Program Manager-Soldier; Operational and Organizational Plans (Mar 87); Draft MNS (11 Sep 92); Joint Service Agreement (14 Dec 93)—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures.